Project
COSMIC 312
Completed ยท 2019 until 2020
Semela David, Stillhard Roman
Type
Clinical Studies
Range
Multicentric, KSSG as participating partner
Units
Status
Completed
Start Date
2019
End Date
2020
Financing
Industry
Study Design
This is a multicenter, randomized, open-label, controlled Phase 3 trial of cabozantinib in
combination with atezolizumab versus sorafenib in subjects with advanced HCC who have not
received previous systemic anticancer therapy.
Brief description/objective
A Randomized, Controlled Phase 3 Study of Cabozantinib
(XL184) in Combination with Atezolizumab versus Sorafenib
in Subjects with Advanced Hepatocellular Carcinoma Who
Have Not Received Previous Systemic Anticancer Therapy
Randomisation 2:1:1:1
Cabozantinib + Atezolizumab
Sorafenib
Cabozantinib